A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer

New England Journal of Medicine - Tập 349 Số 5 - Trang 427-434 - 2003
James Chih‐Hsin Yang1, Leah Haworth1, Richard M. Sherry1, Patrick Hwu1, Douglas J. Schwartzentruber1, Suzanne L. Topalian1, Seth M. Steinberg2, Alice Chen3, Steven A. Rosenberg1
1Surgery Branch
2Biostatistics and Data Management Section
3Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD

Tóm tắt

Từ khóa


Tài liệu tham khảo

Gnarra JR, 1996, Biochim Biophys Acta, 1242, 201

10.1038/ng0594-85

10.1073/pnas.93.20.10589

10.1073/pnas.93.20.10595

Mukhopadhyay D, 1997, Mol Cell Biol, 17, 5629, 10.1128/MCB.17.9.5629

10.1038/20459

10.1073/pnas.192342099

10.1073/pnas.94.17.9102

Haigh JJ, 2000, Development, 127, 1445, 10.1242/dev.127.7.1445

10.1007/s001099900019

10.1038/362841a0

10.1002/(SICI)1097-0045(19980401)35:1<1::AID-PROS1>3.0.CO;2-O

Presta LG, 1997, Cancer Res, 57, 4593

Gordon MS, 2001, J Clin Oncol, 19, 843, 10.1200/JCO.2001.19.3.843

10.2307/2530245

Turner KJ, 2002, Cancer Res, 62, 2957

Mundhenke C, 2001, Clin Cancer Res, 7, 3366

Stadler WM, 1999, J Clin Oncol, 17, 2541, 10.1200/JCO.1999.17.8.2541

Hanada K, 2001, Cancer Res, 61, 5511

Thông tin
Thông tin xuất bản

New England Journal of Medicine

Tập 349 Số 5

427-434

Thông tin tác giả